4.6 Article

Series: Pragmatic trials and real world evidence: Paper 3. Patient selection challenges and consequences

期刊

JOURNAL OF CLINICAL EPIDEMIOLOGY
卷 89, 期 -, 页码 173-180

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jclinepi.2016.12.021

关键词

Pragmatic trial; Real-world evidence; Participant; Recruitment; Enrollment; Representativeness

资金

  1. Innovative Medicines Initiative joint undertaking [115546]
  2. European Union's Seventh Framework Programme (FP7)
  3. EFPIA companies

向作者/读者索取更多资源

This paper addresses challenges of identifying, enrolling, and retaining participants in a trial conducted within a routine care setting. All patients who are potential candidates for the treatments in routine clinical practice should be considered eligible for a pragmatic trial. To ensure generalizability, the recruited sample should have a similar distribution of the treatment effect modifiers as the target population. In practice, this can be best achieved by including within the selected sites all patients without further selection. If relevant heterogeneity between subgroups is expected, increasing the relative proportion of the subgroup of patients in the heterogeneous trial could be considered (oversampling) or a separate trial in this subgroup can be planned. Selection will nevertheless occur. Low enrollment and loss to follow-up can introduce selection and can jeopardize validity as well as generalizability. Pragmatic trials are conducted in clinical practice rather than in a dedicated research setting, which could reduce recruitment rates. However, if a trial poses a minimal burden to the physician and the patient and routine clinical practice is maximally adhered to, the participation rate may be high and loss to follow-up will not be a specific problem for pragmatic trials. (C) 2017 The Authors. Published by Elsevier Inc.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据